Dr. Agarwals Health Care Ltd Q1 FY27 Results

Dr. Agarwals enters Q1 FY27 riding strong fundamentals. FY26 closed with revenue of ₹2,080 Cr (+21.6% YoY), EBITDA at ₹614 Cr (+22.2%), and PAT at ₹168 Cr (+52.4%) — profit growth outpacing sales and earnings delivery ahead of expectations. Q4 alone showed revenue of ₹564 Cr (+22.6% YoY) and margins at 30.2%, signalling sustained pricing power and operational leverage into the new financial year.

The Street is uniformly bullish. Five analysts surveyed offer a consensus buy rating with an average 12-month price target of ₹545 (13.7% upside from ₹482 today), reflecting confidence in the growth trajectory and strategic positioning. FY27 is forecast to deliver revenue growth of 18.7% and earnings growth of 31.2% on an annualised basis, though Q1 specifics will set the tone for how aggressively the company can scale operations without margin erosion.

Strong print: Revenue at or above ₹530 Cr with EBITDA margins holding 29%+ (PAT ₹75–82 Cr+); commentary on merger synergies and facility-opening velocity; full-year guidance maintained or raised. This would signal zero merger disruption and confidence in the 60-center plan. Weak print: Revenue miss (sub-₹500 Cr), margin compression below 28% due to one-time merger costs, or delayed facility openings. Any GST resolution update (positive or negative) could move the dial materially; the ₹20.5 Cr show-cause is an overhang until addressed.

The company has not delivered Q1-specific guidance, but the FY27 forecast of 18.7% revenue growth and 31.2% earnings growth is ambitious but defensible given Q4's +22.6% revenue pace. For Q1 to land on the 18–20% range would be conservative relative to the recent run; the real risk is whether margin expansion (the +22.2% EBITDA beat in FY26) can persist when merger integration is underway. Watch the management commentary on (a) one-time integration charges, (b) facility-opening ramp profile, and (c) any pressure from the GST notice's legal/tax reserves.

Dr. Agarwals reports Q1 FY27 results tomorrow (Aug 4) with revenue and profit growth likely to track 20%+ and the Street's expectations, but three vectors will determine how the print is received:

Dr. Agarwal's Health Care's consolidated revenue from operations grew 26.0% YoY to ₹614 Cr (total income ₹620 Cr, +23.9%), while PAT grew faster at 44.6% YoY to ₹55 Cr — profit outpacing revenue growth for a second straight comparison period. Sequentially, revenue rose 8.9% QoQ, which management called its highest-ever single-quarter sequential growth, and PAT rose 10.1% QoQ; the YoY comparison remains the primary read since eye-care volumes for this chain are not materially seasonal quarter to quarter.

EBITDA rose 25.2% YoY to ₹177 Cr with margin expanding to 28.5% from 28.2% a year ago, and held roughly flat versus Q4 FY26's 28.86%. Consultancy charges for doctors (₹88.3 Cr) and employee benefits (₹121.0 Cr) remained the two largest cost lines, growing broadly in line with revenue. Surgical volumes rose a slower 15.5% YoY to 91,082 cases even as revenue climbed 26%, pointing to rising realization/mix — revenue from Mature Facilities grew a sharper 37.1% YoY to ₹485 Cr, while the newer greenfield sites (23 surgical facilities launched in the trailing six months) are still ramping and, per management, are weighing on incremental margins. PAT growth also benefited from a lower effective tax rate of 26.8% this quarter versus 29.0% a year ago. No exceptional items hit either this quarter or the year-ago quarter at the consolidated level, so the 44.6% PAT growth is a clean like-for-like number, not a one-off.

The stock went into the print at ₹495.75, up 3% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

Against Street forecasts of roughly ₹540 Cr revenue and ₹1.07 EPS for the quarter (Simply Wall St consensus), the company beat comfortably with ₹614 Cr revenue and ₹1.43 basic EPS. Against management's own guidance from the May 21, 2026 concall — sustained FY27 growth at a pace similar to FY26, stable EBITDA margins despite greenfield investment, and 60 new facility openings planned for the year — the quarter is running ahead of plan: 18 facilities were added, comprising 16 new surgical centres (the highest ever in a single quarter), roughly 30% of the full-year facility target hit in the first quarter alone, and margins expanded rather than merely held steady. Corporately, creditors of both AHCL and its listed subsidiary Dr. Agarwal's Eye Hospital approved the scheme of amalgamation on July 2, 2026 (still awaiting NCLT sanction), and the board separately cleared incorporation of a new Nigerian subsidiary on results day, extending an African network that already spans nine countries. CEO Dr. Adil Agarwal called it "an exceptional quarter on multiple fronts," citing the record facility additions and growth "across all of our regions," while flagging "rising greenfield losses" from the 23 facilities opened in the last six months — a framing that matches the numbers, where EBITDA margin gains were a modest 30bps YoY even as PAT growth outpaced revenue growth.